The 36-month beta value for ITCI is at 1.01. Analysts have varying views on the stock, with 5 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ITCI is 98.68M, and currently, shorts hold a 4.19% of that float. The average trading volume for ITCI on July 19, 2024 was 1.22M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ITCI) stock’s latest price update
The stock of Intra-Cellular Therapies Inc (NASDAQ: ITCI) has decreased by -2.05 when compared to last closing price of 76.51. Despite this, the company has experienced a -4.32% fall in its stock price over the last five trading sessions. zacks.com reported 2024-07-09 that The average of price targets set by Wall Street analysts indicates a potential upside of 30.1% in Intra-Cellular (ITCI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
ITCI’s Market Performance
ITCI’s stock has fallen by -4.32% in the past week, with a monthly rise of 8.81% and a quarterly drop of -2.28%. The volatility ratio for the week is 2.48% while the volatility levels for the last 30 days are 3.72% for Intra-Cellular Therapies Inc The simple moving average for the last 20 days is 1.65% for ITCI stock, with a simple moving average of 14.18% for the last 200 days.
Analysts’ Opinion of ITCI
Many brokerage firms have already submitted their reports for ITCI stocks, with Robert W. Baird repeating the rating for ITCI by listing it as a “Outperform.” The predicted price for ITCI in the upcoming period, according to Robert W. Baird is $83 based on the research report published on January 03, 2024 of the current year 2024.
TD Cowen, on the other hand, stated in their research note that they expect to see ITCI reach a price target of $75. The rating they have provided for ITCI stocks is “Outperform” according to the report published on December 11th, 2023.
Morgan Stanley gave a rating of “Overweight” to ITCI, setting the target price at $80 in the report published on April 20th of the previous year.
ITCI Trading at 7.25% from the 50-Day Moving Average
After a stumble in the market that brought ITCI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -11.72% of loss for the given period.
Volatility was left at 3.72%, however, over the last 30 days, the volatility rate increased by 2.48%, as shares sank -0.72% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +5.53% upper at present.
During the last 5 trading sessions, ITCI fell by -4.32%, which changed the moving average for the period of 200-days by +43.87% in comparison to the 20-day moving average, which settled at $73.70. In addition, Intra-Cellular Therapies Inc saw 4.64% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ITCI starting from RIGGS RORY B, who sale 4,462 shares at the price of $75.57 back on Jun 24 ’24. After this action, RIGGS RORY B now owns 116,600 shares of Intra-Cellular Therapies Inc, valued at $337,193 using the latest closing price.
VAN NOSTRAND ROBERT L, the Director of Intra-Cellular Therapies Inc, sale 20,000 shares at $75.91 during a trade that took place back on Jun 18 ’24, which means that VAN NOSTRAND ROBERT L is holding 9,690 shares at $1,518,199 based on the most recent closing price.
Stock Fundamentals for ITCI
Current profitability levels for the company are sitting at:
- -0.26 for the present operating margin
- 0.93 for the gross margin
The net margin for Intra-Cellular Therapies Inc stands at -0.22. The total capital return value is set at -0.22. Equity return is now at value -18.07, with -15.09 for asset returns.
Based on Intra-Cellular Therapies Inc (ITCI), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -6.0. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is -30.34.
Currently, EBITDA for the company is -158.85 million with net debt to EBITDA at 0.95. When we switch over and look at the enterprise to sales, we see a ratio of 15.2. The receivables turnover for the company is 3.91for trailing twelve months and the total asset turnover is 0.69. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.12.
Conclusion
In conclusion, Intra-Cellular Therapies Inc (ITCI) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
